Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →SAGA Diagnostics today announced the launch of its Pathlight tumor-informed multi-cancer MRD test, starting with an indication for early-stage breast cancer.…
Roche has agreed to acquire MRD specialist SAGA Diagnostics and its Pathlight platform in a $595 million bid, further expanding its cancer monitoring…
Sweden's SAGA Diagnostics, a Lund-based MRD specialist, is set for acquisition as Roche builds out MRD infrastructure. Pathlight uses a proprietary combination…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Roche's Foundation Medicine subsidiary agreed to acquire Sweden-headquartered (US-RTP-based) SAGA Diagnostics for up to $595M (upfront plus regulatory and commercial milestones) to build out its molecular residual disease (MRD) infrastructure. The transaction is expected to close in Q3 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / SAGA Diagnostics AB (this deal) | 2026 | $595M | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2026 deals · Roche Holding AG deals · Oncology deals